 Albaha Barqawi
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 18 | 2021 | 1010 | 2.710 |
Why?
| | Cryotherapy | 4 | 2021 | 21 | 2.260 |
Why?
| | Prostate | 3 | 2020 | 150 | 0.920 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 165 | 0.840 |
Why?
| | Imaging, Three-Dimensional | 3 | 2020 | 548 | 0.760 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 767 | 0.580 |
Why?
| | Prostate-Specific Antigen | 8 | 2020 | 167 | 0.530 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2013 | 43 | 0.500 |
Why?
| | Symptom Assessment | 1 | 2013 | 126 | 0.480 |
Why?
| | Ultrasound, High-Intensity Focused, Transrectal | 1 | 2011 | 3 | 0.460 |
Why?
| | Antineoplastic Agents, Hormonal | 3 | 2005 | 145 | 0.380 |
Why?
| | Testosterone | 3 | 2013 | 305 | 0.370 |
Why?
| | Ultrasonography, Interventional | 3 | 2020 | 133 | 0.370 |
Why?
| | Androgen Antagonists | 3 | 2006 | 81 | 0.340 |
Why?
| | Prostatic Hyperplasia | 2 | 2005 | 31 | 0.340 |
Why?
| | Mass Screening | 2 | 2005 | 1038 | 0.340 |
Why?
| | Erectile Dysfunction | 1 | 2005 | 31 | 0.300 |
Why?
| | Hormone Replacement Therapy | 1 | 2005 | 78 | 0.290 |
Why?
| | Self Medication | 1 | 2004 | 13 | 0.280 |
Why?
| | Prazosin | 1 | 2004 | 38 | 0.280 |
Why?
| | Flutamide | 1 | 2003 | 5 | 0.280 |
Why?
| | Plant Preparations | 1 | 2004 | 24 | 0.270 |
Why?
| | Phytotherapy | 1 | 2004 | 69 | 0.270 |
Why?
| | Cryptorchidism | 1 | 2003 | 11 | 0.270 |
Why?
| | Palpation | 1 | 2003 | 16 | 0.270 |
Why?
| | Anticarcinogenic Agents | 1 | 2004 | 76 | 0.260 |
Why?
| | Complementary Therapies | 1 | 2004 | 79 | 0.260 |
Why?
| | Testis | 1 | 2003 | 130 | 0.250 |
Why?
| | Vitamins | 1 | 2004 | 141 | 0.250 |
Why?
| | Male | 21 | 2021 | 60721 | 0.230 |
Why?
| | Combined Modality Therapy | 2 | 2021 | 1240 | 0.230 |
Why?
| | Adenocarcinoma | 2 | 2007 | 800 | 0.220 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1220 | 0.210 |
Why?
| | Kallikreins | 1 | 2020 | 40 | 0.210 |
Why?
| | Image-Guided Biopsy | 1 | 2020 | 35 | 0.210 |
Why?
| | Urination Disorders | 2 | 2013 | 14 | 0.210 |
Why?
| | Dietary Supplements | 1 | 2004 | 430 | 0.210 |
Why?
| | Middle Aged | 11 | 2021 | 28678 | 0.200 |
Why?
| | Health Status | 1 | 2005 | 769 | 0.200 |
Why?
| | Aged | 10 | 2020 | 20026 | 0.200 |
Why?
| | Laparoscopy | 1 | 2003 | 383 | 0.190 |
Why?
| | African Americans | 1 | 2005 | 1096 | 0.190 |
Why?
| | Prospective Studies | 3 | 2021 | 6168 | 0.190 |
Why?
| | Biopsy, Needle | 2 | 2008 | 196 | 0.180 |
Why?
| | Humans | 22 | 2021 | 112255 | 0.160 |
Why?
| | Pilot Projects | 1 | 2021 | 1406 | 0.160 |
Why?
| | Survival Rate | 1 | 2021 | 1851 | 0.160 |
Why?
| | Prostatectomy | 2 | 2007 | 108 | 0.140 |
Why?
| | Andropause | 1 | 2013 | 9 | 0.140 |
Why?
| | Nocturia | 1 | 2013 | 7 | 0.140 |
Why?
| | Urology | 1 | 2013 | 43 | 0.130 |
Why?
| | Dexamethasone | 2 | 2006 | 318 | 0.130 |
Why?
| | Case-Control Studies | 1 | 2021 | 3353 | 0.130 |
Why?
| | Prognosis | 1 | 2021 | 3532 | 0.120 |
Why?
| | Biopsy | 2 | 2007 | 1065 | 0.120 |
Why?
| | Aged, 80 and over | 5 | 2007 | 6779 | 0.110 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4888 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2020 | 11118 | 0.110 |
Why?
| | Quality of Life | 2 | 2020 | 2089 | 0.110 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2008 | 252 | 0.100 |
Why?
| | Societies, Medical | 1 | 2013 | 764 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2020 | 8944 | 0.090 |
Why?
| | Models, Anatomic | 1 | 2008 | 102 | 0.090 |
Why?
| | Risk Factors | 3 | 2005 | 8979 | 0.080 |
Why?
| | Patient Selection | 1 | 2011 | 692 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2006 | 1388 | 0.080 |
Why?
| | Cryosurgery | 1 | 2007 | 57 | 0.080 |
Why?
| | Carboplatin | 1 | 2006 | 138 | 0.080 |
Why?
| | Myocardial Infarction | 1 | 2013 | 1111 | 0.080 |
Why?
| | Adult | 5 | 2007 | 31793 | 0.080 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2007 | 141 | 0.080 |
Why?
| | Stroke | 1 | 2013 | 916 | 0.080 |
Why?
| | Orchiectomy | 1 | 2005 | 57 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2817 | 0.070 |
Why?
| | Doxazosin | 1 | 2004 | 1 | 0.070 |
Why?
| | Penile Erection | 1 | 2004 | 8 | 0.070 |
Why?
| | Finasteride | 1 | 2004 | 10 | 0.070 |
Why?
| | Age Distribution | 1 | 2005 | 402 | 0.070 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2004 | 42 | 0.070 |
Why?
| | Selenium | 1 | 2004 | 35 | 0.070 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 85 | 0.070 |
Why?
| | Inguinal Canal | 1 | 2003 | 5 | 0.070 |
Why?
| | Seminal Vesicles | 1 | 2003 | 12 | 0.070 |
Why?
| | Peritoneal Cavity | 1 | 2003 | 30 | 0.070 |
Why?
| | Vas Deferens | 1 | 2003 | 20 | 0.070 |
Why?
| | Early Diagnosis | 1 | 2005 | 246 | 0.070 |
Why?
| | Seminoma | 1 | 2003 | 17 | 0.070 |
Why?
| | Gastroschisis | 1 | 2003 | 22 | 0.070 |
Why?
| | Anus, Imperforate | 1 | 2003 | 21 | 0.070 |
Why?
| | Guidelines as Topic | 1 | 2005 | 285 | 0.070 |
Why?
| | Patient Care Planning | 1 | 2004 | 165 | 0.060 |
Why?
| | Hypospadias | 1 | 2003 | 22 | 0.060 |
Why?
| | Radiation Injuries | 1 | 2004 | 127 | 0.060 |
Why?
| | Cyclooxygenase 2 | 1 | 2004 | 196 | 0.060 |
Why?
| | Cyclophosphamide | 1 | 2003 | 236 | 0.060 |
Why?
| | Brachytherapy | 1 | 2003 | 96 | 0.060 |
Why?
| | United States | 2 | 2013 | 12170 | 0.060 |
Why?
| | Chromosome Aberrations | 1 | 2003 | 145 | 0.060 |
Why?
| | Drug Utilization | 1 | 2004 | 182 | 0.060 |
Why?
| | Vitamin D | 1 | 2006 | 326 | 0.060 |
Why?
| | Carcinoma | 1 | 2004 | 212 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2005 | 4550 | 0.060 |
Why?
| | Isoenzymes | 1 | 2004 | 367 | 0.060 |
Why?
| | Forecasting | 1 | 2005 | 399 | 0.060 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2002 | 23 | 0.060 |
Why?
| | Testicular Neoplasms | 1 | 2003 | 91 | 0.060 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2004 | 679 | 0.060 |
Why?
| | Ultrasonography | 1 | 2007 | 764 | 0.060 |
Why?
| | Health Surveys | 1 | 2004 | 497 | 0.060 |
Why?
| | Sulfonamides | 1 | 2004 | 439 | 0.050 |
Why?
| | Comorbidity | 1 | 2005 | 1598 | 0.050 |
Why?
| | Family | 1 | 2004 | 569 | 0.050 |
Why?
| | Antioxidants | 1 | 2004 | 569 | 0.050 |
Why?
| | Disease Progression | 2 | 2004 | 2474 | 0.050 |
Why?
| | Socioeconomic Factors | 1 | 2004 | 1206 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2004 | 1130 | 0.050 |
Why?
| | Research Design | 1 | 2004 | 901 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2004 | 1294 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2004 | 1091 | 0.040 |
Why?
| | Smoking | 1 | 2005 | 1627 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2004 | 1237 | 0.040 |
Why?
| | Colorado | 1 | 2004 | 4552 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2004 | 2048 | 0.030 |
Why?
| | Mortality | 1 | 2013 | 327 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2013 | 331 | 0.030 |
Why?
| | Risk | 1 | 2013 | 944 | 0.030 |
Why?
| | Infant | 1 | 2003 | 8024 | 0.030 |
Why?
| | Subtraction Technique | 1 | 2008 | 29 | 0.020 |
Why?
| | Child, Preschool | 1 | 2003 | 9655 | 0.020 |
Why?
| | Rectum | 1 | 2008 | 151 | 0.020 |
Why?
| | Child | 2 | 2003 | 17358 | 0.020 |
Why?
| | Coronary Artery Disease | 1 | 2013 | 693 | 0.020 |
Why?
| | Medical History Taking | 1 | 2007 | 127 | 0.020 |
Why?
| | Syndrome | 1 | 2007 | 342 | 0.020 |
Why?
| | Pedigree | 1 | 2007 | 518 | 0.020 |
Why?
| | Gynecomastia | 1 | 2005 | 6 | 0.020 |
Why?
| | Hot Flashes | 1 | 2005 | 71 | 0.020 |
Why?
| | Veterans | 1 | 2013 | 874 | 0.020 |
Why?
| | Muscular Diseases | 1 | 2005 | 102 | 0.020 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2005 | 64 | 0.020 |
Why?
| | Adolescent | 1 | 2003 | 18579 | 0.020 |
Why?
| | Trastuzumab | 1 | 2004 | 95 | 0.020 |
Why?
| | Computer Simulation | 1 | 2008 | 943 | 0.020 |
Why?
| | Anemia | 1 | 2005 | 164 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 412 | 0.020 |
Why?
| | Cohort Studies | 1 | 2013 | 4937 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2004 | 330 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2005 | 205 | 0.020 |
Why?
| | Osteoporosis | 1 | 2005 | 194 | 0.020 |
Why?
| | Bladder Exstrophy | 1 | 2002 | 17 | 0.020 |
Why?
| | Cystostomy | 1 | 2002 | 9 | 0.020 |
Why?
| | Spinal Dysraphism | 1 | 2002 | 32 | 0.010 |
Why?
| | Urethra | 1 | 2002 | 48 | 0.010 |
Why?
| | Receptor, ErbB-2 | 1 | 2004 | 321 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2002 | 195 | 0.010 |
Why?
| | Neural Tube Defects | 1 | 2002 | 67 | 0.010 |
Why?
| | Animals | 1 | 2004 | 35194 | 0.010 |
Why?
| | Body Composition | 1 | 2005 | 739 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2004 | 623 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1828 | 0.010 |
Why?
| | Mental Disorders | 1 | 2005 | 929 | 0.010 |
Why?
|
|
Barqawi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|